Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
08:44pm, Tuesday, 21'st Oct 2025
Agenus Inc. (NASDAQ:AGEN ) Shareholder/Analyst Call October 21, 2025 4:00 PM EDT Company Participants Stefanie Perna-Nacar - Chief Communications & Government Relations Officer Garo Armen - Founder, E
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
08:00am, Friday, 17'th Oct 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new data from its botensilimab (BOT), a multifunctional, Fc-enhanc
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
07:48am, Thursday, 16'th Oct 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ESMO2025--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025, at
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
07:43am, Tuesday, 09'th Sep 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
08:52am, Friday, 05'th Sep 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the company will participate in the H.C. Wainwright 27th Annual Globa
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
02:04pm, Thursday, 28'th Aug 2025
Agenus Inc. (NASDAQ:AGEN ) Virtual Stakeholder Briefing Conference Call August 27, 2025 8:30 AM ET Company Participants Garo H. Armen - Founder, Executive Chairman & CEO Jennifer S.
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ColorectalCancer--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder
Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates
07:56pm, Monday, 11'th Aug 2025
Agenus (AGEN) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $2.52 per share a year ago.
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
07:30am, Monday, 11'th Aug 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quar
QuantumScape & 2 Other Stocks to Buy for Earnings Acceleration
04:01pm, Thursday, 31'st Jul 2025
QS, CVEO, and AGEN show strong earnings acceleration this month - often a signal of stock price momentum ahead.
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
07:30am, Thursday, 31'st Jul 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results befor
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress across its botensilimab and balstilimab i
Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains?
10:42am, Monday, 14'th Jul 2025
Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
10:42am, Monday, 14'th Jul 2025
Here is how Agenus (AGEN) and CVS Health (CVS) have performed compared to their sector so far this year.
